Serum Institute seeks DCGI approval for Covishield as booster dose

New Delhi, 1/12:Serum Institute of India has sought the drug regulator’s approval to administer Covishield as a booster dose, citing adequate stock of the vaccine in the country and the demand for a booster shot due to the emergence of Omicron coronavirus variant, official sources said.



In an application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, the Director, Government and Regulatory Affairs at Serum Institute of India (SII), cited that the UK’s Medicines and Healthcare products Regulatory Agency has already approved the booster dose of AstraZeneca ChAdOx1 nCoV-19 vaccine, according to the sources.


Singh is learnt to have said in the application that as the world continues to face the pandemic situation, many countries have started administering booster doses of Covid-19 vaccines.

Comments are closed.